Abstract
Purpose :
Trabecular meshwork (TM) stiffness is elevated in glaucoma patients vs. unaffected individuals (Last, IOVS, 2011; Wang et al., 2017). However, glaucoma eyes in these studies were treated with glaucoma medications, a possible confounding factor. Here we explore whether there is a relationship between TM stiffness and conventional outflow resistance in 2 strains of wild-type mice and in a steroid mouse glaucoma model.
Methods :
In all mice, outflow facility (C) was measured by ocular perfusion and TM stiffness (E) was measured by atomic force microscopy on thawed cryosections (Wang et al., EER, 2016). In Study 1, we used untreated wild-type C57BL/6J (n=18) and CBA/J (n=10) mice. In Study 2, we used custom nano-sized polymers loaded with either dexamethasone (DEX; n=25 mice) or vehicle (n=16), injected into the subconjunctival/periocular space of C57BL/6J mice. IOP was measured twice per week (TonoLab).
Results :
In Study 1, C was slightly lower in CBA/J vs. C57BL/6J (Mean±SD: 6.17 ± 2.91 vs. 6.28 ± 2.18 mmHg/nl/min) while the TM was stiffer in CBA/J (3.08 ± 3.55 kPa) than in C57BL/6J (2.20 ± 1.12 kPa); however, neither difference was statistically significant. In Study 2, IOP of DEX mice was elevated vs. control mice on the day of sacrifice (27.1 ± 2.7 vs. 20.5 ± 3.2mmHg; P<0.001). C of DEX mice was lower than for control mice (3.05 ± 1.47 vs. 4.09 ± 1.71mmHg; P=0.192). The TM in DEX mice was stiffer than that in control mice, but this difference was not statistically significant (2.38 ± 1.31 vs. 1.99 ± 0.91 kPa; P=0.357). Importantly, TM stiffness significantly correlated with outflow resistance (1/C) within each study (Study 1: R2=0.35, P=0.006; Study 2: R2=0.41, P=0.002; Figure 1).
Conclusions :
TM stiffness is positively correlated with conventional outflow resistance in two wild-type mouse strains and after DEX treatment in C57BL/6J mice. This is consistent with human data and suggests that TM stiffness is intimately involved in establishing outflow resistance. This finding motivates development of techniques to measure TM stiffness in vivo, as a surrogate for TM function, and development of novel therapeutic approaches based on reducing TM stiffness to lower IOP.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.